ENT 01

Drug Profile

ENT 01

Alternative Names: ENT-01; Enterin-01; kenterin

Latest Information Update: 30 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enterin
  • Class Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Constipation

Most Recent Events

  • 15 May 2017 Phase-I/II clinical trials in Constipation (In adults, In the elderly) in USA (PO) (NCT03047629)
  • 03 Feb 2017 Preclinical trials in Constipation in USA (PO) (Enterin pipeline, February 2017)
  • 03 Feb 2017 Enterin plans a phase I/IIa trial for Constipation in USA (NCT03047629)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top